Maxigen BiotechTPE:1783 -1.55%87 FCF Margin % is 23.98% as of Dec. 2025, which is 9% above its 10-year median of 21.93. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued). Among 815 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 95.21% on this metric.
The historical rank and industry rank for Maxigen Biotech's FCF Margin % or its related term are showing as below:
TPE:1783'
s FCF Margin % Range Over the Past 10 Years
Min: -11.29 Med: 21.93 Max: 42.01
Current: 25.58
During the past 13 years, the highest FCF Margin % of Maxigen Biotech was 42.01%. The lowest was -11.29%. And the median was 21.93%.
TPE:1783's FCF Margin % is ranked better than 95.21% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs TPE:1783: 25.58
Maxigen Biotech FCF Margin % Related Terms
Maxigen Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: FCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a FCF Margin % of 23.98% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Maxigen Biotech and its competitors. This is near median its historical median of 21.93. According to the industry distribution chart, Maxigen Biotech ranks #39 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 4.8%.
Is Maxigen Biotech's FCF Margin % too high?
Maxigen Biotech's current FCF Margin % of 23.98% is near median its 10-year median of 21.93. Based on the distribution chart, Maxigen Biotech ranks #39 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #39 out of 815 companies for FCF Margin %. This places Maxigen Biotech in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Maxigen Biotech and its competitors. Maxigen Biotech's current FCF Margin % is 23.98%, which is near median its own 10-year median of 21.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.10 — trading 37.5% below its estimated fair value. The current FCF Margin % is 23.98%, which is near median its 10-year median of 21.93. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current FCF Margin % is 23.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
FCF Margin %: 23.98% (near median its 10-year median of 21.93)
GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
